ANDA 205444, held by Actavis Labs Fl Inc. Oxcarbazepine.
As of Nov 16, 2026, ANDA 205444 (Oxcarbazepine), held by Actavis Labs Fl Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2026 | Original application | Tentative approval |
| Oxcarbazepine150MG · tablet, extended release;oral | Oxcarbazepine | None (tentative approval) |
| Oxcarbazepine300MG · tablet, extended release;oral | Oxcarbazepine | None (tentative approval) |
| Oxcarbazepine600MG · tablet, extended release;oral | Oxcarbazepine | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters